Centocor Ortho Biotech is a biopharmaceutical company that has undergone significant changes and integrations. It was a subsidiary of Johnson & Johnson, formed through the merger of Centocor and Ortho-McNeil Pharmaceutical's biotech operations [1]. In 2011, Johnson & Johnson consolidated its pharmaceutical companies, including Centocor Ortho Biotech, into a single entity known as Janssen Biotech, Inc. [2]. This move aimed to streamline operations and create a unified brand for its biologics and specialty medicines [2].
What happened to Centocor Ortho Biotech?
Centocor Ortho Biotech no longer operates as a distinct entity. It was integrated into Janssen Biotech, Inc. as part of a larger reorganization by its parent company, Johnson & Johnson [2]. This integration was a strategic decision to consolidate its various pharmaceutical businesses under one umbrella [2].
What are Janssen Biotech's key products?
Following the integration, Janssen Biotech, Inc. has been responsible for marketing and developing a portfolio of significant biologic drugs. These include treatments for various conditions such as inflammatory diseases, autoimmune disorders, and cancer [2]. Some prominent medications associated with Janssen Biotech include Remicade (infliximab) and Stelara (ustekinumab), which were developed by Centocor prior to the merger [3][4].
When did Centocor Ortho Biotech become Janssen Biotech?
The transition from Centocor Ortho Biotech to Janssen Biotech, Inc. occurred in 2011, when Johnson & Johnson consolidated its pharmaceutical subsidiaries [2]. This rebranding and organizational change marked the end of Centocor Ortho Biotech as an independent operational name [2].
Who is the parent company of Janssen Biotech?
Janssen Biotech, Inc. is a subsidiary of Johnson & Johnson, a global healthcare company [2]. Johnson & Johnson oversees the operations and strategic direction of its various pharmaceutical, medical device, and consumer health segments [1][2].
What is the history of Centocor and Ortho-McNeil?
Centocor was a biopharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. Ortho-McNeil Pharmaceutical was a division of Johnson & Johnson specializing in various therapeutic areas. The formation of Centocor Ortho Biotech represented a strategic alignment of their respective biotech capabilities under the Johnson & Johnson umbrella [1]. This collaboration aimed to leverage their combined expertise in biologics development and commercialization [1].
What is Remicade's patent status?
Remicade (infliximab), a drug developed by Centocor before its integration into Janssen Biotech, has faced patent challenges. Information regarding the patent exclusivity and expiry dates for Remicade and its biosimilars can be found on specialized resources like DrugPatentWatch.com [3]. These resources track patent landscapes and exclusivity periods for pharmaceutical products.
How does Remicade compare to other autoimmune disease treatments?
Remicade is a biologic medication that works by inhibiting tumor necrosis factor-alpha (TNF-α), a key mediator in inflammatory processes. It is used to treat conditions such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Its efficacy and side effect profile are compared against other biologic agents targeting different inflammatory pathways, as well as traditional disease-modifying antirheumatic drugs (DMARDs) [4].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.janssen.com/
3. https://www.drugpatentwatch.com/drug/remicade
4. https://www.janssen.com/our-products